
A panel of experts review ASCO 2024 and the need for future research in CDK4/6 inhibitors.
A panel of experts review ASCO 2024 and the need for future research in CDK4/6 inhibitors.
Dr. Dempsey discusses how CDK4/6 Inhibitors have impacted medication costs for breast cancer care, and the importance of implementing cost containment strategies to alleviate the situation.
Drs. Hanna and Rugo discuss possible access improvements in regards to CDK4/6 inhibitors.
Dr. O’Shaughnessy discusses how she weighs clinical benefits against cost considerations in regards to selecting a CDK4/6 inhibitor.
A panel of experts discuss the variables of dosage and patient adherence in regards to managing toxicities from CDK4/6 inhibitors.
A medical expert navigates toxicity management in patients being treated with ribociclib.
Dr. Rugo details her management strategy in regards to GI toxicities.
Dr. Dempsey details how different types of endocrine therapies have impacted toxicities within her patients.
A panel of experts compare the toxicity profiles of abemaciclib and ribociclib.
Published: August 18th 2025 | Updated: August 25th 2025
Published: August 19th 2025 | Updated: August 22nd 2025
Published: June 6th 2025 | Updated: August 18th 2025
Published: June 27th 2025 | Updated: July 1st 2025
Published: February 20th 2025 | Updated: February 21st 2025
Published: January 16th 2025 | Updated: January 29th 2025
259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831
© 2025 MJH Life Sciences®
All rights reserved.